# Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

> **NCT03525210** · PHASE3 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 271 (actual)

## Conditions studied

- Human Papilloma Virus
- Hiv
- Organ Transplants

## Interventions

- **BIOLOGICAL:** 9-valent HPV vaccine

## Key facts

- **NCT ID:** NCT03525210
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2019-09-01
- **Final completion:** 2020-07-15
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525210, "Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03525210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*